MRNA EQUITY Biological Products, (No Disgnostic Substances) 2027 Quantitative Forecast

Moderna, Inc. Common Stock (MRNA) Stock Price Prediction 2027

Multi-horizon algorithmic price targets, Wall Street consensus calibration, reverse-DCF growth expectations & options volatility valuation

$199.33
+$2.54 (+1.29%)
Market Close: Nov 19, 2026
1-Year Base Target
$165.32 -17.1%
Constant-P/E algorithmic trajectory
Wall St. Consensus
$165.32 Bull $207
Institutional analyst mean target
Fair Value (PEG/DCF)
$165.32 Model Par
52W Range: $22.28 – $280.80
AI Quant Stance
HOLD 41/100
RSI 41.4 • MACD Bearish • Downtrend

Executive Forecast Synopsis (2027)

Synthesized fundamental, multiple & technical thesis for MRNA

AI Research Note

MRNA Price Forecast 2027: Our AI models project that MRNA stock will fall to approximately $165.32 by 2027. This represents a potential 17.1% contraction from the current trading price of $199.33. The overall market sentiment for MRNA is currently bearish, based on a combination of proprietary technical signals and fundamental analysis.

Fundamental Analysis: Trading with its most recent quarterly earnings growing by -85.1%. MRNA shows a complex fundamental profile. Our model evaluates these metrics alongside sector peers and historical performance to derive the 2027 price target. If the company exceeds its current growth projections, there may be further upside beyond our base case scenario.

Technical Outlook: The stock is technically in a downtrend phase. The Relative Strength Index (RSI) is currently 41.4, which suggests the stock is trading in a neutral range. Traders should monitor key support and resistance levels closely, as a breakout or breakdown from current price consolidation will be the primary catalyst for the stock reaching the 2027 predicted target.

Quant Signal & Technical Posture

Composite equity rating reconciled with 1-year target trajectory

Score: 40.7/100
Composite Equity Stance
HOLD (Quant Score 41/100) — HOLD (Near-Term Consolidation / -17.1% 1Y Base Model)
Active Technical & Price Action Triggers
  • Recent pattern: Doji - Indecision pattern
  • Price near support at $195.52
MACD Regime: Bearish
Volume Tape: Slight_Accumulation

MRNA Trajectory & Forecast Curve

Projected price curve from spot ($199.33) across 30D–3Y horizons

Term Structure of Price Targets

Calibrated to Wall Street consensus curve

30D – 3Y
Horizon Target Price Implied Return
30 Days Near-Term $196.61 -1.4%
90 Days 1 Quarter $190.83 -4.3%
6 Months Medium-Term $182.32 -8.5%
1 Year Base Model $165.32 -17.1%
Wall Street 12M Consensus Target: $165.32

1-Year Scenario Distribution (Bull / Base / Bear)

Probability-weighted regime outcomes around the 12-month forecast horizon

Regime Matrix
Bull Case 30% Prob
$206.65 +3.7%

Best case scenario if strong fundamentals and market conditions align

Base Case 50% Prob
$165.32 -17.1%

Expected scenario based on current growth trajectory

Bear Case 20% Prob
$115.72 -41.9%

Downside scenario if market headwinds or disappointing results

LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA Path Scenario ($165 Target): Simulated 5-Day Swing & LEAP Payoffs

Compare $21,527 for 100 MRNA shares against risk-defined 5-day option spreads and long-dated LEAP structures.

5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq A

Dec 18 $190P / $220-$260C Seagull

Sell 1x $190P · Buy 1x $220/$260C · 32d

Net Entry $140 Debit
T+5d @ +5% Move +$693 (+23.1% RoM)
Max Risk / Buffer -11.7% Put Cushion ($3,005 Mgn)
5d Edge & Liquidity 1.1x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Reverse-DCF Implied Growth, Supply-Chain Moat & R&D Velocity

Proprietary deep-tech expectations gap, supply-chain bottleneck scoring & patent/filing velocity

Deep-Tech & Valuation Intelligence
Reverse-DCF: What's Priced In Priced Beyond Precedent
Market-Implied 5Y CAGR: 75.2%
Analyst Consensus CAGR: 12.2%
Expectation Gap (Implied vs Est): +63.0 pp
Universe: SPDR S&P Biotech ETF (10%/yr hurdle rate)
Supply-Chain Moat & Nx Model Bottleneck 6/10
Moat: None • Position: Drug Discovery Biotech (drug_design)
1Y Modeled
0.17x
3Y Modeled
0.18x
5Y Thesis Adj
0.20x
R&D & Commercialization Velocity
90D Commercialization Mentions: 49 disclosures
Commercialization Themes:
mRNA Therapeutics (49)

Fair Value & Core Fundamentals

PEG-adjusted intrinsic valuation & balance-sheet multiples

Forward P/E
-44.83x
P/S Ratio (TTM)
31.53x
Rev Growth (YoY)
29.2%
EPS Growth (YoY)
-85.1%
Market Cap
$79,625M
52-Week High
$280.80
52-Week Low
$22.28

Technicals & Institutional Money Flow

Momentum oscillators, volume accumulation & key price levels

Slight_Accumulation
Volume Tape: Slight_Accumulation

Volume-weighted price action shows near-term supply/distribution pressure; watch support levels for stabilization.

RSI (14-Day)
41.4
Neutral
MACD Signal
Bearish
Primary Trend
Downtrend
Chaikin Money Flow
0.069
Money Flow Index
48.4
200-Day SMA
$217.13

Options Volatility Valuation: 1-Year Target Strike Strategy

Comparing LEAP Call Implied Volatility & Breakeven against the 1-Year Model Target — Derivative Strategy Signal, NOT an Equity Stock Rating

Options Strategy Only Strategy Score: 61/100
OPTIONS STRATEGY: OVERWRITING / CREDIT SPREADS
SELL COVERED CALLS / COLLECT PREMIUM (Options Overpriced vs. Target)
This is an Options Volatility Valuation signal (comparing Call IV to 1Y target), NOT a sell rating on MRNA shares.
Rich Call Premium (Write / Overwrite)
Premium Collected
$59.80/sh
Profit at 1Y Target
$59.80/sh
Option Writer ROI
+100.0%
Applicable Structures
Covered Call (safest) • Naked Call (risky) • Credit Spread (defined risk)
Why Options Are Flagged for Premium Selling: The $220 Call (Dec 2027) requires MRNA to exceed $279.80 at expiration just to break even. Because the conservative constant-P/E 1Y model target is $165.32, buying out-of-the-money calls carries negative expected value (Buyers lose 100.0% even if target hits. Premium is overpriced for -15.5% move.), whereas shareholders overwriting covered calls capture rich implied volatility.
Wall St. 1Y Target
$165.32
-15.5% vs spot
Evaluated Call Strike
$220.00
Exp: Dec 17, 2027
Call Mark Premium
$59.80
30.6% of spot price
Call Buyer Breakeven
$279.80
Above 1Y base target
Delta / Implied Prob
63.8%
Option market odds
Contract Liquidity
138 OI
Vol: 10 • Nov 19

Unusual Options Flow Alert (Short-Term Derivative Tape)

Short-term institutional sweep & implied volatility anomaly monitor (distinct from long-term equity rating)

Strong Alert (Options Flow)
Flow Alert Score
90/100
Tape Classification
Strong Alert (Options Flow)
Unusual Volume Score
80.3
Implied Volatility Spike
+93.4%
Derivative Tape Readout: Short-Term Derivative Tape: Strong unusual activity detected. Review for potential entry. (Reflects options volume & IV anomalies, not a long-term stock rating.)

Frequently Asked Questions (MRNA 2027 Outlook)

What is the MRNA stock price prediction for 2027?

Based on our AI analysis, MRNA is predicted to reach $165.32 by 2027, representing a potential 17.1% decrease from the current price of $199.33.

Is MRNA stock a good buy right now?

Our analysis rates MRNA as a HOLD (AI Quant Score 40.7/100) based on current technical and fundamental indicators. With a projected 17.1% downside in our 1-year constant-P/E model, investors should consider their risk tolerance and investment horizon.

What is MRNA 52-week high and low?

MRNA has a 52-week high of $280.80 and a 52-week low of $22.28. The stock is currently trading 29.0% below its 52-week high.

What is the technical analysis for MRNA?

MRNA is currently in a downtrend trend. The RSI of 41.4 indicates the stock is trading in neutral territory. Traders should monitor support and resistance levels for potential entry points.

Quantitative Research Disclaimer: Price predictions, reverse-DCF expectations, and options volatility strategies are generated algorithmically from historical financial data, analyst consensus estimates, and live options chains. They are provided strictly for informational and research purposes and do not constitute investment advice. Always conduct independent due diligence before executing equity or derivative transactions.